Sarepta

Sarepta touts clean data for commercial grade Duchenne gene therapy, clearing key hurdle to PhIII
Endpoints
Tue, 05/18/21 - 11:11 am
Sarepta
Duchenne Muscular Dystrophy
clinical trials
gene therapy
Mark Your Calendar For February PDUFA Dates
Yahoo/Benzinga
Sun, 01/31/21 - 10:18 pm
FDA
Adamas Pharmaceuticals
Gocovri
Mallinckrodt
StrataGraft
Regeneron
evinacumab
Sanofi
Sarepta
TG Therapeutics
Sarepta collects half a billion in follow-on
BioCentury
Thu, 11/8/18 - 08:46 pm
Sarepta
3 Biotech Stocks That Could Soar in September
Motley Fool
Sun, 08/27/17 - 06:26 pm
biotech
fitusiran
Alnylam
PTC Therapeutics
Translarna
Sarepta
Exondys 51
Sarepta May Have More Upside After Sales Data
Seeking Alpha
Thu, 01/19/17 - 11:47 am
Sarepta
Duchenne Muscular Dystrophy
Exondys 51
eteplirsen
Will Insurers Pay For Sarepta’s DMD Drug?
Barron's
Thu, 12/15/16 - 10:05 am
Sarepta
Duchenne Muscular Dystrophy
Exondys 51
Medicaid
payers
insurers
3 Biotechs That Just Announced Successful Phase 2 Trials
24/7 Wall St
Sun, 06/12/16 - 10:03 pm
clinical trials
TEV-1845
Teva Pharmaceutical
migraines
Sarepta
eteplirsen
Duchenne Muscular Dystrophy
Sarepta shares soar on FDA voting questions
CNBC
Fri, 04/22/16 - 09:38 pm
Sarepta
FDA
eteplirsen
Duchenne Muscular Dystrophy
Sarepta, Biomarin vie for DMD approval, priority review voucher
BioPharma Dive
Mon, 08/24/15 - 11:47 am
Sarepta
Biomarin
Duchenne Muscular Dystrophy
FDA
priority review
review vouchers
Sarepta Earnings Preview: 3 Things to Watch For
Investopedia
Tue, 05/5/15 - 08:42 am
Sarepta
earnings
Sarepta jumps on fresh optimism for an early approval
Fierce Biotech
Thu, 01/16/14 - 11:34 am
Sarepta
Duchenne Muscular Dystrophy
eteplirsen
Amarin, Sarepta And Vanda: Teachable Moments In Biotech
Seeking Alpha
Sun, 11/17/13 - 12:13 pm
Amarin
Sarepta
Vanda
7 Disruptive Drugs for the Next Decade
Motley Fool
Wed, 10/9/13 - 10:42 pm
Tecfidera
Biogen Idec
Bristol-Myers Squibb
Eliquis
Pfizer
Roche
Kadcyla
Immunogen
sofosbuvir
Gilead
ibrutinib
Pharmacyclics
Sarepta
eteplirsen
LX4211
Lexicon Pharmaceuticals
3 Key Points From Sarepta's Eteplirsen Study Update (And They're Positive)
TheStreet.com
Thu, 09/26/13 - 10:35 am
Sarepta
eteplirsen
Genentech
GSK
Duchenne Muscular Dystrophy
Four Promising Biotech Stocks With Upcoming Catalysts
Minyanville
Thu, 08/22/13 - 10:05 am
GSK
Sarepta
Gilead
sofosbuvir
SGX203
SGX942
Soligenix
drisapersen
Sarepta shares jump after disappointing test for rival drug
Reuters
Fri, 08/16/13 - 10:33 am
Prosensa
drisapersen
Duchenne Muscular Dystrophy
GSK
Sarepta
eteplirsen
The Best- And Worst-Performing Biotech Stocks July 19 To July 26
Forbes
Mon, 07/29/13 - 12:27 pm
TearLab
Array Biopharma
Furiex Pharmaceuticals
InterMune
Prosensa
Boston Scientific
Orexigen
Momenta
Ironwood
INSYS Therapeutics
Sequenom
OncoMed
Abraxis
Sarepta
Epizyme
Tesaro
Synta Pharmaceuticals
Bluebird Bio
Exelixis
Lexicon Pharmaceuticals
Intercept Pharma
GTx
Biotech Stocks Under Pressures, Focus On IPOs
Property Mentor Group
Fri, 07/26/13 - 11:37 am
IPOs
Sequenom
Invovio
Aeterna Zentaris
Sarepta
InterMune
Cryolife
BiogenIdec
Boston Scientific
Varian Medical
Warner Chilcott
Sarepta To Seek Early U.S. Approval For Muscular Dystrophy Drug
TheStreet.com
Wed, 07/24/13 - 09:54 am
Sarepta
FDA
Duchenne Muscular Dystrophy
eteplirsen
Is The DMD Market Becoming Too Crowded?
Motley Fool
Tue, 07/9/13 - 05:14 pm
Duchenne Muscular Dystrophy
Sarepta
eteplirsen
drisapersen
GSK
PTC Therapeutics

Pages